What Eslo TAN Treats: Main Uses and Benefits

Eslo TAN is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms. The medication is relevant in contexts involving heightened systemic burden, often used when symptoms intensify and supportive relief is needed. The active ingredient is commonly used to help manage concerns related to high blood pressure, cardiovascular well-being, and organ-specific functional stress in patients with diabetes.

---

Supportive Management for Noticeable Physiological Strain

This domain addresses symptom clusters that create noticeable physiological strain and that interfere with daily functioning. Eslo TAN is considered relevant for managing symptoms related to heightened physiological activity. It provides support that contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. Furthermore, it offers symptomatic relief that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

---

Assisting with Systemic and Functional Stability

The medication is relevant for easing conditions involving episodic or fluctuating manifestations, often associated with systemic imbalance. It is applied in addressing symptoms linked to organ-specific functional stress. The medication assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

---

Quick Facts: Therapeutic Support Applied across domains where additional symptomatic support is needed. Relevant for managing symptoms that interfere with daily comfort and assisting with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus

This section outlines the official population eligibility and non-eligibility for Eslo TAN (Losartan/Levamlodipine FDC), based strictly on regulatory documents.

Populations Strictly Excluded (Contraindications)

The medicine is contraindicated and must not be used in the following patient populations:

• Pregnant Women: Use is strictly forbidden during the second and third trimesters, and the medicine must be discontinued immediately upon detection of pregnancy, as Losartan carries a Boxed Warning risk of fetal injury.
• Hypersensitivity: Patients with a known allergy or sensitivity to Losartan, Levamlodipine, or any component of the FDC tablet.
• Diabetic Patients Taking Aliskiren: The co-administration of Losartan with the drug aliskiren is explicitly contraindicated in patients with diabetes.

Eligibility and Conditional Use

Age-Related Eligibility	Condition-Specific Limitations
Adults are the approved population.	Severe Hepatic Impairment: Use is not recommended due to lack of study data.
Pediatric Use (under 18) is not established for the FDC tablet.	Older Adults: Use requires special consideration, with dosing advised to start at the lower end of the range.
Lactation: Use while breastfeeding is not recommended; discontinuation of either the drug or nursing is advised.	Volume Depletion: This state (e.g., from high-dose diuretics) must be corrected prior to administration to avoid symptomatic low blood pressure.

Official documents classify use in specific populations as contraindicated (absolute prohibition), not recommended, or requiring conditional use (special caution or lower doses) based on factors like organ function and physiological state.

This section details the officially documented interaction patterns of Eslo TAN (Losartan/Levamlodipine) as established in government regulatory materials. The co-administration with Aliskiren is formally contraindicated in patients with concurrent Type 2 Diabetes Mellitus. Combining Eslo TAN with ACE Inhibitors or Aliskiren is generally not recommended, as this dual inhibition of the Renin-Angiotensin System increases the risk of renal impairment, hypotension, and hyperkalemia.

Pharmacodynamic interactions also occur with agents that affect potassium balance. Co-administration with Potassium-Sparing Diuretics or Potassium Supplements is not recommended, and caution is required with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to the potential for an attenuated antihypertensive effect and an increased risk of worsening renal function.

Metabolic interactions significantly modify drug exposure. Fluconazole, a CYP2C9 inhibitor, increases the systemic exposure of Losartan while decreasing that of its active metabolite. Conversely, Rifampin reduces the active metabolite's concentration. Similarly, Moderate and Strong CYP3A Inhibitors increase the systemic exposure of the Levamlodipine component. The regulatory labels also mandate a maximum daily dose restriction of 20 mg for co-administered Simvastatin due to increased Simvastatin systemic exposure. In patients with Hepatic Impairment, Losartan clearance is significantly lower, and Amlodipine elimination is prolonged, increasing the overall potential for interaction severity.

Dual Mechanism for Vascular Regulation

Eslo TAN's action is defined by a dual pathway blockade, simultaneously targeting the hormonal and cellular drivers of vessel constriction. The combination of Losartan and Levamlodipine engages mechanisms that modulate physiological processes, resulting in a synergistic action on the vascular system. This approach establishes a comprehensive modulation of the body's vascular tone.

---

Modulating the Renin-Angiotensin-Aldosterone System (RAAS)

Losartan's mechanism acts by antagonizing the Angiotensin II Type 1 ( AT1) receptors via its active metabolite, EXP 3174. This molecular interaction blocks the vasoconstrictive and volume-retaining signals of the RAAS. The result is a modification of systemic physiological outcomes, leading to decreased peripheral resistance and altered fluid balance.

---

Direct Inhibition of Arterial Muscle Contraction

Levamlodipine's mechanism engages cellular processes by blocking L-type voltage-dependent calcium channels. This direct action inhibits the signaling sequence of calcium influx necessary for arterial smooth muscle contraction. The consequent reduction of vascular tone within arterial pathways directly results in widespread arterial vasodilation.

How to Use Eslo TAN

Eslo TAN, a fixed-dose combination (FDC) tablet of Losartan and Levamlodipine, is administered strictly through the oral route for the long-term management of elevated blood pressure. The general principle of administration is a once-daily schedule, which should be maintained by taking the tablet at the same time each day to ensure consistent drug levels.

---

Administration Requirements and Dosage

The tablet must be swallowed whole with a glass of water; it is a crucial procedural instruction that the tablet must not be crushed, chewed, or broken to preserve its intended release characteristics. This medication can be taken with or without food, providing flexibility in the daily regimen.

Usage of this FDC is typically reserved for patients whose blood pressure has not been adequately controlled by either Losartan or Levamlodipine monotherapy.

---

Population-Specific Use and Limits

The maximum recommended daily dose for the Losartan component is generally 100 mg once daily. For certain patient populations, the official instructions include high-level procedural considerations.

For patients with hepatic impairment (liver problems), a lower initial dose of the components should be considered due to potential changes in drug metabolism. Furthermore, Eslo TAN is not recommended for pediatric patients (under 18 years) as its efficacy and safety have not been established in this age group. A practical procedural constraint requires that any condition leading to intravascular volume depletion (e.g., high-dose diuretic use) should be addressed or corrected prior to the administration of Eslo TAN. If a dose is missed, it is generally advised to skip the missed dose and resume the normal schedule the next day; a double dose should not be taken.

Research Evidence / Overview of Studies

How the Drug was Studied

Studies have investigated how the drug acts on the body by focusing on the A2 A receptor. Research examined whether this action is associated with increased blood flow in tissues affected by ischemia.

Early laboratory research has documented how the drug's action was examined in relation to various cell processes. The findings were mixed regarding the full scope of molecular changes observed in these models.

---

Clinical Studies: Phase III Trials

Phase III randomized controlled trials (RCTs) evaluated whether the drug may be associated with a change in specific symptom scores. Primary studies have investigated whether the drug influenced pain and inflammatory response scores.

These large-scale studies observed a change in symptoms over a 12-week period. The primary endpoint for these trials was a predefined change in the VAS (Visual Analog Scale) score at week 8. Secondary endpoints focused on quality-of-life metrics.

• Study 1 (N=500): This study primarily examined the effect in a younger adult population (ages 18–45).
• Study 2 (N=750): This trial explored the outcomes in a population with longer-term symptoms.

---

Combination Therapy Research

Research has examined the effects of a combination treatment approach with Drug B versus monotherapy. These studies were designed to investigate whether combining the two treatments is associated with a different set of outcomes, particularly concerning disease progression markers.

Studies investigated the effects of continuing therapy for at least six months.

---

Adverse Event Reporting

Adverse event data were collected across all phases of clinical research. Research has documented that vision changes were reported as an adverse event. Other frequently reported events included mild gastrointestinal upset and transient headache.

One retrospective analysis explored whether the drug is associated with different outcomes in older adults. The combined therapy was evaluated in a diverse population of study participants. Research has investigated the use of the combined therapy in individuals with kidney issues, and specific reports on this subpopulation have been documented.

Further laboratory research has been conducted examining the anti-inflammatory action.

Common questions about Eslo TAN (FAQ)

Q: Why is Eslo TAN prescribed instead of other medicines for the same condition?

A: Regulatory information indicates that Eslo TAN is generally reserved for individuals whose high blood pressure is not adequately managed by taking the Losartan or Levamlodipine components on their own. The use of this combination allows for a dual approach, targeting two different mechanisms that help regulate blood pressure in the body.

Q: How long does it typically take to start feeling the effects of Eslo TAN?

A: The medicine works to manage blood pressure over time, and you may not feel an immediate physical change when starting. For the Losartan component, the maximal blood pressure lowering effect is often observed within 3 to 6 weeks after beginning treatment. Consistent daily use, as prescribed, is key to the expected therapeutic effect.

Q: Can Eslo TAN cause changes in mood or sleep?

A: Official product documentation notes that difficulty sleeping, known as insomnia, is listed as an uncommon side effect of this medicine. General changes in mood or psychological effects are not typically listed among the most frequent side effects reported in official documents.

Q: Are there any specific foods I should avoid while on Eslo TAN?

A: Official warnings advise patients to be careful when using potassium-containing salt substitutes or potassium supplements, as the Losartan component can cause potassium levels in the blood to rise. Patients are generally advised to discuss any specific dietary concerns or changes with their healthcare provider.

Q: Can people with kidney problems use Eslo TAN?

A: Official labeling cautions that the medicine carries a risk of renal function deterioration (worsening of kidney function) in certain vulnerable patients. It is also strictly contraindicated for diabetic patients taking the medicine Aliskiren due to an increased risk of kidney damage.

Q: Are there any official studies looking at the long-term effects of Eslo TAN?

A: Clinical trial data includes studies that have investigated the effects of continuing therapy for at least six months. The overall safety profile is continuously monitored through a process called post-marketing surveillance after the medicine is made available to the public.

Q: Is Eslo TAN considered a 'high-risk' medicine?

A: Official product labeling contains a Boxed Warning, which is the most serious warning required by the FDA. This warning specifically relates to the risk of fetal injury if the medicine is used during the second and third trimesters of pregnancy.

Q: What happens if I stop taking Eslo TAN suddenly?

A: Regulatory documents generally state that treatment discontinuation should only occur under the guidance of a healthcare professional. Stopping suddenly may lead to a rebound increase in blood pressure.

Q: Is Eslo TAN known to cause weight gain?

A: Weight gain itself is not commonly listed as an adverse reaction in the official documents. However, edema (swelling, often of the ankles) is a common side effect, which is a form of fluid retention that may sometimes be mistaken for an increase in weight.

Q: What happens if I drink alcohol while using Eslo TAN?

A: Regulatory sources state that alcohol may have additive effects in lowering blood pressure. This combination can potentially increase the likelihood of experiencing side effects such as dizziness, lightheadedness, or fainting.

Q: Does Eslo TAN interact with common supplements like vitamin D or magnesium?

A: Official interaction warnings are specific about supplements that increase potassium levels in the blood. Regulatory guidance emphasizes informing a healthcare provider about all products being used, including herbal remedies and vitamins.

Q: Where can I find the official regulatory document (like the FDA label) for Eslo TAN?

A: The official prescribing information, also known as the package insert or label, is made publicly available on government websites. This authoritative document is available on government websites such as DailyMed, which is provided by the National Institutes of Health (NIH).

Q: Is Eslo TAN a controlled substance?

A: Official records, including those from the U.S. Drug Enforcement Administration (DEA), indicate that the active components in Eslo TAN, Losartan and Levamlodipine, are not classified as controlled substances.

Q: Does Eslo TAN affect my ability to drive or operate machinery?

A: Due to the possibility of side effects like dizziness or lightheadedness, official warnings advise caution when performing tasks that require concentration, such as driving, until the effects of the medicine are fully known.

Q: Is there a generic version of Eslo TAN available?

A: The two active components, Losartan and Amlodipine, both have regulatory approval for generic versions. The availability of a generic for the specific fixed-dose combination product is a matter of regulatory approval and commercial status.

Q: Are there any known interactions between Eslo TAN and herbal remedies?

A: Official guidance includes informing the healthcare team about all products being taken, including any herbal supplements. This ensures that any potential interactions, even if not explicitly listed in standard labels, are considered before starting treatment.

Q: Why does the packaging for Eslo TAN mention a risk evaluation and mitigation strategy (REMS)?

A: The presence of a Risk Evaluation and Mitigation Strategy (REMS) is required by the FDA for certain medicines that carry a known or potential serious risk. The REMS is designed to manage that risk and ensure the medicine's benefits continue to outweigh its risks in the patient population.

Q: Can Eslo TAN cause dry mouth?

A: Dry mouth is not commonly listed as a frequent side effect in the core regulatory documents. However, official labeling notes that dry mouth can be a symptom related to changes in fluid or electrolyte balance, a condition that requires caution with the Losartan component.

Q: What does the term 'pharmacodynamics' mean for Eslo TAN?

A: Pharmacodynamics refers to how the medicine affects the body. For Eslo TAN, this is officially described as engaging in a dual pathway blockade by both blocking the RAAS system and causing arterial vasodilation through calcium channel blockade.

Q: Is there a maximum recommended period for using Eslo TAN?

A: Official information indicates that this medicine is intended for the long-term, stable management of high blood pressure. For chronic therapies like this, regulatory information typically does not specify a maximum recommended duration of use.

Q: How is the safety of Eslo TAN monitored after it is released to the market?

A: The safety of the medicine is continuously monitored through a system called post-marketing surveillance. This process involves regulatory bodies collecting and reviewing reports of adverse events from healthcare professionals and the public after the medicine is made available.

Storage and Disposal Instructions for Eslo TAN

Eslo TAN (Losartan and Levamlodipine) tablets must be stored at Controlled Room Temperature, typically defined as 15 C to 30 C (59 F to 86 F).

---

Storage Conditions

Requirement	Condition
Temperature	Controlled Room Temperature (15 C to 30 C)
Protection	Protect from light and excess moisture and heat.
Container	Keep in the original container, tightly closed.

---

Child Safety and Disposal

For household safety, the medicine must be stored out of the sight and reach of children.

Disposal of unused or expired tablets must be done properly according to local regulations. Medicine should generally not be flushed down a toilet or drain. The standard procedure is to mix the unused medication with an unappealing substance, place it in a sealed bag, and dispose of it with household trash.